|Delivery||Report Code||Available Format|
|24-72 Working Hours||LS11113|
Protein assays are utilized in life science research to detect the presence of protein in a sample. Estimation of protein fixation is important for protein cleaning, electrophoresis, cell science, atomic science, and research applications. Although there are a wide variety of protein assays available, none of the assays can be used without first considering their suitability for an application. Each assay has its own advantages and limitations and often it is necessary to obtain more than one type of assay for various research applications. The global protein assay market is expected to witness considerable growth during the forecast period (2017 – 2023), mainly due to the increasing investment by pharma and biotech companies in research and development (R&D), as well as funding by governments of various countries for proteomics research.
The global protein assay market is segmented on the basis of product, type, technology, application, end user and geography. Based on product, the global market is segmented into reagents, kits, and instruments and accessories. The reagents are expected to contribute the largest share in the global protein assay market.
On the basis of type, the global protein assay market is divided into dye binding assays, copper-ion-based assays, test strip-based assays, and other assays. The dye-binding assays held the largest share of the global market in 2016, mainly attributable to the rising utilization of dye-binding assays for diagnosing various diseases.
On the basis of technology, the global protein assay market is segmented into absorbance-based protein measures, colorimetric protein tests, and fluorescence-based protein examines. The absorbance-based protein assay technology was the largest contributor to the global market, mainly attributable to the expanding effectiveness and accuracy of absorbance-based protein tests due to innovation in the technology of protein assays.
On the basis of application, the global protein assay market is segmented into drug discovery and development, disease diagnosis, and others. The disease diagnosis segment is expected to witness the highest growth during the forecast period which can be attributed to the rising acceptance of protein assays for the diagnosis of immune system diseases, cancer, and diseases related to liver, kidney and bone marrow.
Growth Drivers and Restraints
The rising investment in pharmaceutical and biotechnology R&D, favorable government policies for proteomics research, and the presence of a large number of players in the global protein assay market are the key factors driving the growth of the market during the forecast period. According to a publication by Pharmaceuticals Research and Manufacturers of America (PhRMA), the member organizations (pharmaceutical companies) of PhRMA spent approximately $58.8 billion on R&D, accounting for the largest part of all the biopharmaceutical R&D spending in the U.S, in 2015. However, high cost of multiplex assay hardware is limiting the growth of global protein assay market.
Various new biomarker identification systems and the emerging new uses for the protein assays provide numerous opportunities to the players in the global protein assay market. For instance, in June 2017, Gyros Protein Technologies AB launched a new version of its anti-drug antibody (ADA) solution for the immunogenicity market. Gyrolab ADA solution enables customers to automatically run drug-tolerant ADA assays in a time-efficient manner reducing hands-on time, using small volumes of patient samples and reagents, and shortening run-times.
North America was the largest market for protein assay in 2016, followed by Europe and Asia-Pacific. Asia-Pacific is expected to witness the highest growth during the forecast period. The growth in protein assay market in developing economies such as China, India, and Japan is primarily due to the increasing R&D expenditure in life science, and increase in the funding by various government and private organizations for proteomics research.
The competition in the global protein assay market is very high, therefore, many players are concentrating on introducing various innovative approaches in this field.
In Feb 2017, Promega Corporation announced the development of a benchtop capillary electrophoresis (CE) instrument in collaboration with Hitachi High-Technologies Corporation. The Spectrum Compact CE system meets small batch and single sample requirements in DNA analysis and performs both sequencing and fragment analysis at a short notice. The Spectrum Compact CE System allows laboratories the freedom to carry NGS validation, PCR sizing and microsatellite analysis, single nucleotide polymorphism, de novo sequencing and mutation detection.
In April 2017, Bio-Rad Laboratories Inc. launched StarBright Blue 700, fluorescent color marked optional antibodies, for use in multiplex western smudging with a two-to-four-crease lower limit than IR800 named antibodies, the present standard.
In June 2015, Thermo Fisher Scientific Inc., introduced the Orbitrap Fusion Lumos Tribrid mass spectrometer and in 2017, the company came up with new advancements, for example, Integrated Ultraviolet Photo separation (UVPD) that enables specialists to perform substantial and little atom structure assurance on a Lorentz focus (LC) time scale; and New Advanced Peak Determination (APD) calculation that is intended to enhance execution of most proteomic work processes with high peptide and protein ID rates.
Some of the other key players operating in the global market are ThermoFisher Scientific, Inc., PerkinElmer, Inc., Bio-Rad Laboratories, Inc., Promega Corporation, GE Healthcare, Merck KGaA, Cell Signalling Technology, Inc., Abcam PLC, Lonza Group, BioVision Inc., Bio-Techne Corporation (Novus Biologicals) and G-Biosciences Inc.
By End User